At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Belataceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Pharmacokinetic Study in De Novo Renal Transplant Subjects Receiving a Belatacept Based Immunosuppressant Regimen
In Brief
A Phase 2 clinical trial evaluating Belatacept for Renal Transplantation. Completed, enrolled 14 participants across 5 sites in 3 countries.
Detailed Summary
The purpose of this study is to assess the pharmacokinetics and safety of belatacept in de novo renal transplant subjects treated with belatacept-based immunosuppressant medication
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Transplantation
CountriesArgentina, Mexico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2007
Enrollment StartMar 2008
Primary CompletionMar 2009
Study CompletionSep 2012
TodayJul 2026
First PostedDec 21, 2007
Enrollment StartMar 1, 2008
Primary CompletionMar 1, 2009
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.5 years ago
Interventions
Belataceptdrug
IV infusion